Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Neena Brizmohun
Australia has introduced new civil penalties and amended criminal offense provisions for breaches of its therapeutic product advertising rules. More reforms to the advertising regulations are expected soon.
Australia has introduced new civil penalties and amended criminal offence provisions for breaches of its therapeutic product advertising rules. More reforms to the advertising regulations are expected soon.
There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).
The European Medicines Agency wants to hear testimonies from the public about serious side effects that have been observed in patients treated with quinolone- and fluoroquinolone-containing medicinal products.
Indian laboratories that manufacturers employ to test their products will now need to be registered with health-care product regulator CDSCO.
A new guidance from the country's Medical Device Authority explains what companies must do if they want to import unregistered devices for demonstration or educational purposes.